RA
CORT icon

Riversedge Advisors’s Corcept Therapeutics CORT Stock Holding History

Riversedge Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$254K Buy
+2,201
New +$237K 0.03% 298

Other funds holding CORT

VFP
Vilga Financial Planning Fair Lawn, New Jersey $168M AUM 23.03% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
WPC
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
BCG
Breakwater Capital Group Paramus, New Jersey $844M AUM 15.36% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

Riversedge Advisors's CORT Position: Q3 2026 in Review

Riversedge Advisors opened a new position in Corcept Therapeutics (CORT) in Q3 2026: 2,201 shares worth $254K. The stake represents 0.03% of the portfolio and ranks #298 among its holdings.

12 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • Riversedge Advisors held 2,201 shares of Corcept Therapeutics worth $254K as of Q3 2026.
  • Corcept Therapeutics was a new Riversedge Advisors position in Q3 2026.
  • Corcept Therapeutics made up 0.03% of Riversedge Advisors's portfolio in Q3 2026, its #298 holding.
  • 12 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Riversedge Advisors's 13F filing for Q3 2026, filed 9 Oct 2026.